Last reviewed · How we verify

Placebo as Capsules

Eli Lilly and Company · Phase 3 active Small molecule

Placebo as Capsules is a Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 3 development for Control arm in phase 3 clinical trials (specific indication unknown).

Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes.

Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes. Used for Control arm in phase 3 clinical trials (specific indication unknown).

Likelihood of approval
61.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Big-pharma sponsor +3.0pp
    Eli Lilly and Company is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030 —
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namePlacebo as Capsules
SponsorEli Lilly and Company
ModalitySmall molecule
PhasePhase 3

Mechanism of action

Placebo is an inert substance used as a control in clinical trials. Any observed effects result from patient expectation, the therapeutic context, and natural disease progression rather than direct molecular action. Placebo responses can be substantial in certain conditions, particularly those with subjective symptom components.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo as Capsules

What is Placebo as Capsules?

Placebo as Capsules is a Small molecule drug developed by Eli Lilly and Company, indicated for Control arm in phase 3 clinical trials (specific indication unknown).

How does Placebo as Capsules work?

Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes.

What is Placebo as Capsules used for?

Placebo as Capsules is indicated for Control arm in phase 3 clinical trials (specific indication unknown).

Who makes Placebo as Capsules?

Placebo as Capsules is developed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).

What development phase is Placebo as Capsules in?

Placebo as Capsules is in Phase 3.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing